Fig. 2

Compounds used in this study: diabody-based ADCs tc-ADC (anti-TAG72, containing the chemically cleavable TCO linker), vc-ADC (anti-TAG72, containing the enzymatically cleavable valine-citrulline linker), and nb-ADC (non-binding, anti-PSMA, containing the TCO linker), linker-drug building blocks (1 and 2), and tetrazine-containing activator (3) and probe (4)